Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial.

The simultaneous use of deferioxamine (DFO) and deferiprone (DFP) has an additive effect in iron excretion in transfusion-dependent thalassemic patients. In a prospective study, we evaluated the safety and effectiveness of combined therapy with these two chelators. Fifty patients with beta-thalassemia were uniformly treated with DFP for 4 days per week and combined therapy with DFP and DFO for 3 days of the week. Efficacy was evaluated by ferritin and cardiac shortening fraction (SF). Hepatic hemosiderosis was also assessed by estimation of the T2 relaxation time by magnetic resonance in a subgroup of patients. Forty-three patients completed 1 year of therapy. Mean ferritin decreased from 3363.7 +/- 2144.5 microg/L to 2323.2 +/- 1740.8 microg/L (P < 0.0001). The reduction was significant even in the group of patients with ferritin <2500 microg/L. Significant improvement in T2 relaxation and SF was observed. The most common adverse events were gastrointestinal symptoms (20%) and transaminasemia (18%). The rate of agranulocytosis was 4.2 cases per 100 patient-years. Prolonged use of combined therapy with DFP and DFO is effective in decreasing iron load and improving cardiac function. Its possible association with higher incidence of agranulocytosis emphasizes the need for close monitoring.
AuthorsAntonis Kattamis, Vassilios Ladis, Helen Berdousi, Nikolaos L Kelekis, Efthymia Alexopoulou, Ioannis Papasotiriou, Kalliopi Drakaki, Irini Kaloumenou, Aggeliki Galani, Christos Kattamis
JournalBlood cells, molecules & diseases (Blood Cells Mol Dis) 2006 Jan-Feb Vol. 36 Issue 1 Pg. 21-5 ISSN: 1079-9796 [Print] United States
PMID16386928 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Pyridones
  • Siderophores
  • deferiprone
  • Ferritins
  • Deferoxamine
  • Adolescent
  • Adult
  • Blood Transfusion
  • Deferoxamine (administration & dosage, adverse effects)
  • Drug Therapy, Combination
  • Female
  • Ferritins (blood)
  • Hemosiderosis (complications, therapy)
  • Humans
  • Pyridones (administration & dosage, adverse effects)
  • Siderophores (administration & dosage, adverse effects)
  • beta-Thalassemia (blood, complications, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: